CAMBRIDGE, Mass. & STOCKHOLM--(BUSINESS WIRE)--Newly published clinical data demonstrate that people on extended-interval prophylaxis regimens with ELOCTATE® [Antihemophilic Factor (Recombinant), Fc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results